Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection (IMMUNONCOVID)
A Prospective, Controlled, Randomized, Multicenter Study of the Efficacy of an Autophagy Inhibitor (GNS561), an Anti-NKG2A (Monalizumab) and an Anti-C5aR (Avdoralimab) Compared to the Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.
Sponsor: Centre Leon Berard
This PHASE2 trial investigates Advanced or Metastatic Hematological or Solid Tumor and SARS-CoV-2 (COVID-19) Infection and is currently completed. Centre Leon Berard leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2021 — Oct 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
Status: Suspended → Recruiting
-
Jul 2020 — Jan 2021 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE2
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Leon Berard
For direct contact, visit the study record on ClinicalTrials.gov .